Black Diamond Therapeutics (BDTX) closed at $1.66 on November 5, 2026, down 12.6% from the previous close, on volume of 554,570 shares (30-day average 748,519).
Data as of November 5, 2026.
Globe Newswire (Wed, 2-Sep 4:01 PM ET)
Globe Newswire (Wed, 5-Aug 4:01 PM ET)
BDTX Phase 2 Silevertinib Results Update Scheduled—Key Milestone Approaches for EGFRm NSCLC Therapy
Market Chameleon (Wed, 20-May 6:32 AM ET)
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Black Diamond Therapeutics trades on the NASDAQ stock market under the symbol BDTX.
As of November 5, 2026, BDTX stock price declined to $1.66 with 554,570 million shares trading.
BDTX has a beta of 2.36, meaning it tends to be more sensitive to market movements. BDTX has a correlation of 0.17 to the broad based SPY ETF.
BDTX has a market cap of $95.10 million. This is considered a Micro Cap stock.
Last quarter Black Diamond Therapeutics reported $0 in Revenue and -$.17 earnings per share. This fell short of revenue expectation by $-30 million and exceeded earnings estimates by $.03.
In the last 3 years, BDTX traded as high as $7.66 and as low as $1.20.
The top ETF exchange traded funds that BDTX belongs to (by Net Assets): VTI, IWM, FESM, DFSV, SMLF.
BDTX has underperformed the market in the last year with a price return of -54.1% while the SPY ETF gained +9.7%. BDTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.7% and -20.2%, respectively, while the SPY returned -4.7% and -5.2%, respectively.
BDTX support price is $1.81 and resistance is $2.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDTX shares will trade within this expected range on the day.
